Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Thermo Fisher Scientific Inc / Equity Bottom-Up

<ul><li>Thermo Fisher Scientific was able to engage in strong execution and display solid operational discipline in 2023.</li><li>For that year, the company reported a revenue of $42.9 billion, an adjusted operating income of $9.81 billion and adjusted earnings per share of $21.55.</li><li>Thermo Fisher Scientific attributes these achievements to its efforts of delivering differentiated short-term performance while also strengthening its long-term competitive position.</li></ul>

Thermo Fisher Scientific was able to engage in strong execution and display solid operational discipline in 2023.For that year, the company reported a revenue of $42.9 billion, an adjusted operating income of $9.81 billion and adjusted earnings per share of $21.55.Thermo Fisher Scientific attributes these achievements to its efforts of delivering differentiated short-term performance while also strengthening its long-term competitive position.

Thermo Fisher Scientific: 6 Major Factors Driving Its Growth In 2024! - Financial Forecasts

<ul><li>Thermo Fisher Scientific delivered a disappointing set of results as the company was unable to meet the revenue and earnings expectations of Wall Street.</li><li>The company has been enhancing its commercial intensity in the quarter to assist its customers through the environment and seize more opportunities.</li><li>During the quarter, Thermo Fisher delivered good core business growth driven by its transplant diagnostic, immunodiagnostics, and microbiology businesses.</li></ul>

Thermo Fisher Scientific delivered a disappointing set of results as the company was unable to meet the revenue and earnings expectations of Wall Street.The company has been enhancing its commercial intensity in the quarter to assist its customers through the environment and seize more opportunities.During the quarter, Thermo Fisher delivered good core business growth driven by its transplant diagnostic, immunodiagnostics, and microbiology businesses.

Thermo Fisher Scientific Inc.: Can The Acquisition of CorEvitas Be A Game Changer? – Key Drivers

<ul><li>Thermo Fisher performed reasonably well in Q1 with 6% core organic revenue growth that was above Wall Street expectatis.</li><li>Pandemic-related revenue came in as expected, with $140 million of testing revenue and $180 million of vaccines and therapies revenue.</li><li>Regarding the segment details, the Life Sciences Solutions segment reported a decline in revenue and organic revenue, driven by the moderation in pandemic-related revenue.</li></ul>

Thermo Fisher performed reasonably well in Q1 with 6% core organic revenue growth that was above Wall Street expectatis.Pandemic-related revenue came in as expected, with $140 million of testing revenue and $180 million of vaccines and therapies revenue.Regarding the segment details, the Life Sciences Solutions segment reported a decline in revenue and organic revenue, driven by the moderation in pandemic-related revenue.

Thermo Fisher Scientific Inc.: The GeneProof Partnership & Other Developments

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>With multiple mutations, Omicron may require modifications in the existing vaccines. With fast mover advantage and superior efficacy, <a href="https://www.smartkarma.com/entities/moderna-inc" target="_blank" data-smartkarma-citation="entities:28744:1" rel="noopener">Moderna Inc (MRNA US)</a> seems to be a clear winner of the situation.</li>
<li>Moderna’s current expectation to deliver 2–3 billion doses in 2022 is likely to be revised upwards with the fast spread of Omicron vaccine and full approval of booster doses.</li>
<li>Moderna shares have reasonable valuation compared to its peers. Higher visibility into 2022 and beyond will lead to re-rating opportunity.</li>
</ul>


With multiple mutations, Omicron may require modifications in the existing vaccines. With fast mover advantage and superior efficacy, Moderna Inc (MRNA US) seems to be a clear winner of the situation.
Moderna’s current expectation to deliver 2–3 billion doses in 2022 is likely to be revised upwards with the fast spread of Omicron vaccine and full approval of booster doses.
Moderna shares have reasonable valuation compared to its peers. Higher visibility into 2022 and beyond will lead to re-rating opportunity.


Moderna (MRNA US): To Cash in on Omicron Fear

Latest News from the World’s Leading Innovators

Granite Bay Capital

An innovation focussed investment company

Granite Bay Capital is an innovation focussed investment company with a deep focus on the companies at the leading edge of innovation across major themes such as AI, ubiquitous computing, sustainability, automation and longevity.

Thematic (Sector/Industry)

<p>Headline Developments Nassim Taleb, the celebrated Black Swan author and mathematician, has published a paper trashing bitcoin.  In the paper (excerpts below), Taleb claims the theoretical value of bitcoin is zero, saying it is not a currency, can be neither a short or long term store of value, cannot operate as a reliable inflation hedge and, “worst of all”, does not constitute “not even remotely” a tail protection vehicle for catastrophic episodes (i.</p>

Headline Developments Nassim Taleb, the celebrated Black Swan author and mathematician, has published a paper trashing bitcoin.  In the paper (excerpts below), Taleb claims the theoretical value of bitcoin is zero, saying it is not a currency, can be neither a short or long term store of value, cannot operate as a reliable inflation hedge and, “worst of all”, does not constitute “not even remotely” a tail protection vehicle for catastrophic episodes (i.

United States

Thermo Fisher Scientific, Inc. manufactures scientific instruments, consumables, and chemicals.  The Company offers analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals, and supplies to pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions, and government agencies.

Thermo Fisher Scientific Inc (TMO US)

Thermo Fisher Scientific: 6 Major Factors Driving Its Growth In 2024! - Financial Forecasts

Thermo Fisher Scientific was able to engage in strong execution and display solid operational discipline in 2023. For that year, the company...

Baptista Research

Thermo Fisher Scientific Inc.: Can The Acquisition of CorEvitas Be A Game Changer? – Key Drivers

Thermo Fisher Scientific delivered a disappointing set of results as the company was unable to meet the revenue and earnings expectations of Wall...

Baptista Research

Thermo Fisher Scientific Inc.: The GeneProof Partnership & Other Developments

Thermo Fisher performed reasonably well in Q1 with 6% core organic revenue growth that was above Wall Street expectatis. Pandemic-related revenue...

Baptista Research

Moderna (MRNA US): To Cash in on Omicron Fear

Moderna is set to fly high on the continuous increasing demand for its Covid vaccine and rich pipeline beyond Covid. Emerging Omicron variant is...

Tina Banerjee

Weekly Innovation Review (WIRE) #37

Nassim Taleb, the celebrated Black Swan author and mathematician, has published a paper trashing bitcoin. In the paper, Taleb claims the...

Granite Bay Capital